Biblio

Author [ Title(Desc)] Type Year
Filters: Author is Rocha, Vanderson  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Nagler A, Rocha V, Labopin M, Unal A, Ben Othman T, Campos A, Volin L, Poire X, Aljurf M, Masszi T, et al. Allogeneic Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia in Remission: Comparison of Intravenous Busulfan Plus Cyclophosphamide (Cy) Versus Total-Body Irradiation Plus Cy As Conditioning Regimen--A Report From the Acute Leukemia Worki. J Clin Oncol. 2013.
Radujkovic A, Dietrich S, Blok H-J, Nagler A, Ayuk F, Finke J, Tischer J, Mayer J, Koc Y, Sorà F, et al. Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors - A retrospective study by the EBMT Chronic Malignancies Working Party. Biol Blood Marrow Transplant. 2019.
B
Barban JBernardo, Simões BPinto, Moraes BDel Guerra, da Anunciação CRehem, da Rocha CSantos, Pintor DCristina Q, Guerra DCristina, Silva DAndrade, Brandão Ede Castro, Kerbauy F, et al. Brazilian Nutritional Consensus in Hematopoietic Stem Cell Transplantation: Adults. Einstein (Sao Paulo). 2020;18:AE4530.
C
Prado GVillas Boa, Mendes ETeixeira, Martins RCristina R, Perdigão-Neto LVieira, Freire MPinheiro, Spadão F, Lima VAugusto Ca, Rossi F, Guimarães T, Levin ASara, et al. Carbapenem-resistant Serratia marcescens bloodstream infection in Hematopoietic Stem Cell Transplantation patients: will it be the next challenge?. Transpl Infect Dis. 2021:e13630.
Carneiro TXavier, Marrese DGregolin, Santos MGonçalves, Gonçalves MVescovi, Novis YAugusta Sa, Rizzatti EGil, Rocha V, Sandes AFreire, de Lacerda MPitombeira, Arrais-Rodrigues C. Circulating Extracellular Vesicles as a Predictive Biomarker for Acute Graft-Versus-Host Disease. Exp Hematol. 2022.
Randi BAzevedo, Higashino HRyoiti, da Silva VPonzio, Salomão MChiarastel, Pignatari ACarlos Cam, Abdala E, Vasques F, da Silva CArrais Rod, da Silva RLuiz, Lazari CDos Santos, et al. COVID-19 in hematopoietic stem cell transplant recipients during three years of the pandemic: a multicenter study in Brazil. Rev Inst Med Trop Sao Paulo. 2024;66:e17.
Randi BAzevedo, Higashino HRyoiti, da Silva VPonzio, Xavier EMenezes, Rocha V, Costa SFigueiredo. COVID-19 in hematopoietic stem-cell transplant recipients: A systematic review and meta-analysis of clinical characteristics and outcomes. Rev Med Virol. 2023:e2483.
Randi BA, Guimarães T, Spadao Fde S, Higashino HR, Lazari CDos S, Xavier EM, Rocha V, Costa SF. COVID-19 surveillance in a bone marrow transplantation unit: experience from a Brazilian tertiary-care teaching hospital. Support Care Cancer. 2024;32(4):271.
D
Neffá PPereira, Filho JSchmidt, Ramos JFernandes, Okay TSuely, Castelli JBianchi, Rocha V, Costa SFiqueiredo, Batista MVieira. Disseminated Skin Lesions After Allogeneic Hematopietic Stem Cell Transplantation. Clin Infect Dis. 2018;67(4):639-641.
E
de Oliveira FNivaldo, Ferreira SCleusa, Nishiya AShoko, Mendrone-Junior A, Batista MVieira, Rocha V, Costa SFigueiredo. Evaluation of Dengue, Zika virus, and Chikungunya virus transmission by blood components in recipients of haematopoietic stem cell transplantation. Transfus Med. 2023.
H
Balassa K, Danby R, Rocha V. Haematopoietic stem cell transplants: principles and indications. Br J Hosp Med (Lond). 2019;80(1):33-39.
Angelucci E, Matthes-Martin S, Baronciani D, Bernaudin F, Bonanomi S, Cappellini MDomenica, Dalle J-H, Di Bartolomeo P, de Heredia CDíaz, Dickerhoff R, et al. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica. 2014;99(5):811-820.
Buzo BFernando, Ramos JFernandes, Rossetti RAriza Marq, Salles N, Medrone-Júnior A, Rocha V, Nastri ACatharina. Hepatitis B virus among hematopoietic stem cell transplant recipients: antiviral impact in seroconversion, engraftment and mortality in a Latin American center. Transpl Infect Dis. 2020:e13243.
I
Flor-Park MV, Kelly S, Preiss L, Custer B, Carneiro-Proietti ABF, Araujo AS, Loureiro P, Maximo C, Rodrigues DOW, Mota RA, et al. Identification and characterization of hematopoietic stem cell transplant candidates in a sickle cell disease cohort. Biol Blood Marrow Transplant. 2019.
Arcuri LJavier, Nabhan SKanaan, Cunha R, Nichele S, Ribeiro AAlice Feit, Fernandes JFolloni, Daudt LEsteves, Rodrigues ALuiza Melo, Arrais-Rodrigues C, Seber A, et al. Impact of CD34 cell dose and conditioning regimen on outcomes after Haploidentical donor hematopoietic stem cell transplantation with post-transplant cyclophosphamide for relapsed/refractory severe aplastic anemia: Haploidentical HCT with PTCy for SAA. Biol Blood Marrow Transplant. 2020.
Cappelli B, Scigliuolo GM, Boukouaci W, Rafii H, Volt F, Kenzey C, Maio KT, Chabannon C, Corbacioglu S, Rocha V, et al. Impact of the human leucocyte antigen (HLA)-B leader peptide dimorphism and HLA-A expression on outcomes of stem cell transplantation for sickle cell disease. Br J Haematol. 2021.
Bazarbachi A, Boumendil A, Finel H, Castagna L, Dominietto A, Blaise D, Diez-Martin JL, Tischer J, Gulbas Z, Wallet HL, et al. Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma - a LWP-EBMT study. Br J Haematol. 2019.
L
Heidrich V, Knebel FH, Bruno JS, de Molla VC, Miranda-Silva W, Asprino PF, Tucunduva L, Rocha V, Novis Y, Fregnani ER, et al. Longitudinal analysis at three oral sites links oral microbiota to clinical outcomes in allogeneic hematopoietic stem-cell transplant. Microbiol Spectr. 2023:e0291023.
Törlén J, Ringdén O, Le Rademacher J, Batiwalla M, Chen J, Erkers T, Ho V, Kebriaei P, Keever-Taylor C, Kindwall-Keller T, et al. Low CD34 Dose is Associated with Poor Survival after Reduced Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant. 2014.
M
Lin C, Schwarzbach A, Sanz J, Montesinos P, Stiff P, Parikh S, Brunstein C, Cutler C, Lindemans CA, Hanna R, et al. Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials. Transplant Cell Ther. 2023.
Carvalho NBarbosa, de Freitas VLúcia Tei, Seguro FSalles, Bezerra RCristina, Fatobene G, Nakanishi ÉYoshie Shi, Visnadi H, Martinez G, Batista MVieira, Rocha V, et al. Multiple myeloma and Chagas disease: qPCR as a marker for preemptive antiparasitic therapy: a case reports series and review. Rev Inst Med Trop Sao Paulo. 2024;66:e10.
Hayashi H, Volt F, Sanz J, Petersen E, Dhedin N, Hough R, Milpied N, Angelucci E, Yakoub-Agha I, Michallet M, et al. Myeloablative unrelated cord blood transplantation in adolescents and young adults with acute leukemia. Biol Blood Marrow Transplant. 2019.
O
Fernandes JFolloni, Nichele S, Arcuri LJavier, Ribeiro L, Netto GZamperlini, Loth G, Rodrigues ALuiza Melo, Kuwahara C, Koliski A, Trennepohl J, et al. Outcomes after Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Patients with Primary Immunodeficiency Diseases. Biol Blood Marrow Transplant. 2020.
Paviglianiti A, Maio KTozatto, Rocha V, Gehlkopf E, Milpied N, Esquirol A, Chevallier P, Blaise D, Gac A-C, Leblond V, et al. Outcomes of advanced Hodgkin lymphoma after umbilical cord blood transplantation: a Eurocord and EBMT Lymphoma and Cellular Therapy & Immunobiology Working Party study. Biol Blood Marrow Transplant. 2018.
Xavier E, Cornillon J, Ruggeri A, Chevallier P, Cornelissen JJ, Andersen NS, Maillard N, Nguyen S, Blaise D, Deconinck E, et al. Outcomes of Cord Blood Transplantation Using Reduced Intensity Conditioning for Chronic Lymphocytic Leukemia: a Study on Behalf of Eurocord and Cord Blood Committee of Celular Therapy and Immunobiology Working Party(CTIWP), Chronic Malignancies Working Pa. Biol Blood Marrow Transplant. 2015.

Pages